Clinical Trials

1. Imaging Cells in Monoclonal Antibody Therapy for Lymphoma
2. A Dose-Finding Study of CpG 7909 in Previously Treated Chronic Lymphocytic Leukemia
3. Zevalin Radionimmunotherapy with High-Dose Melphalan and Stem Cell Transplant for Multiple Myeloma (MC048A)
4. Genetic Epidemiology of B-Cell Lymphoproliferative Disorders
5. Daily Oral Polyphenon E in Asymptomatic Rai Stage 0-II Patients with Chronic Lymphocytic Leukemia (MC0419)
6. Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treated Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia
7. Immunosuppressant, Alefacept (Amevive), in the Treatment of Cutaneous T-Cell Lymphoma and Peripheral T-Cell Non-Hodgkin Lymphoma (LS058C)
8. Systemic Administration of (Edmonston Strain) of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide in Patients with Recurrent or Refractory Multiple Myeloma (MC038C)
9. A Phase I/II Study of the Raf Kinase/VEGFR Inhibitor Sorafenib (Bay 43-9006) in Combination with the mTOR Inhibitor RAD001 (Everolimus, Certican) in Patients with Relapsed Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma
10. A Phase I and Pharmacological Clinical Trial of 17-Allylamino-17-demethoxygeldanamycin (17-AAG) and Cytarabine (Ara-C) in Refractory (Resistent) Leukemia and Myelodysplastic Syndrome (MDS)
11. Treatment Study for Patients Diagnosed with High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
12. A Phase 3 Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults
13. Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD)
14. A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma [Diffuse Large B-Cell Lymphoma (DLBCL)] Using Daily Enzastaurin (LY317615.HCl)
15. H23750, The Effect of Diflunisal (Dolobid) (IND 68092) On Familial Amyloidosis: A randomized, double blind, placebo controlled, international multi-center trial of Diflunisal on neurologic disease progression in 200 familial amyloidal patients
16. N0682, A Phase II Study of Denileukin Diftitox in Combination with Rituximab (Rituxan) in Previously Untreated Follicular B-cell Non-Hodgkin Lymphoma Patients
17. Combination Chemotherapy (Methotrexate, Nelarabine) in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia
18. MC0784, Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab (Rituxan) followed by Consolidation with Lenalidomide (Revlimid) for Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
19. MC0785, Antibody Therapy with Alemtuzumab (Campath), Rituximab (Rituxan), and GMCSF (Sargramostim) for Initial Treatment of High Risk Chronic Lymphocytic Leukemia (CLL)
20. Phase II Study of Rituximab (Rituxan) Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma
21. Phase 2 Study to Evaluate the Safety and Efficacy of Monoclonal Antibody Lumiliximab in Combination with Fludarabine, Cyclophosphamide (Cytoxan), and Rituximab (Rituxan) Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
22. Phase II Study of the Histone Deacetylase Inhibitor PXD101 for the Treatment of Myelodysplastic Syndrome (MDS)
23. Randomized Phase III Clinical Trial Comparing Outcomes of Immunologic Autograft Engineering Versus Standard Autograft Collection in Patients Undergoing Autologous Stem Cell Transplantation for Lymphoma
24. A Phase I Study of Weekly Oral ZEN-012, a Small Molecule Anti-Cancer Agent, in Patients With Advanced Cancer and Lymphoma
25. SG040-0005, A Randomized, Phase IIb Placebo-controlled Study of RICE Chemotherapy (Rituximab, Ifosfamide, Carboplatin, and Etoposide) with and without SGN-40 (anti-CD40 humanized monoclonal antibody) for Second-line Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
26. A Phase 2, Study of Carfilzomib in Patients with Relapsed Multiple Myeloma
27. A Phase II Trial of CC-4047 (Actimed) Plus Dexamethasone (Decadron) in Patients with Relapsed or Refractory (Resistant) Multiple Myeloma
28. AAML0431, The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years
29. Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
30. Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia (ALL) That Has Relapsed in the Central Nervous System (CNS) or Testes
31. MC0482, Phase III Study of Stem Cell Transplantation Compared to Parenteral Melphalan and Oral Dexamethasone in the Treatment of Primary Systemic Amyloidosis (AL)
32. AALL06N1, "A Study of Neurocognitive Function in Children Treated for Acute Lymphocytic Leukemia (ALL)"
33. ACF4375g: An Open-Label, Phase 1b, Dose-Escalation Study of the Safety and Pharmacology of the Anti-CD40 Monoclonal Antibody SGN-40 Administered in Combination with Bortezomib (Velcade, PS-341) in Patients with Relapsed or Refractory (resistant) Multiple Myeloma
34. A Phase Ib Study of SGN-40 (anti-huCD40 mAb) in Combination with Rituximab (Rituxan) and Gemcitabine (Gemzar) for the Treatment of Patients with Relapsed or Refractory (resistant) Diffuse Large B Cell Lymphoma (DLBCL)
35. MC078B, A Phase I/II, Prospective, Open-Label Study to Determine the Safety and Efficacy of CC-4047 (Actimed) in Patients with Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis
36. A Phase I Study of Weekly Oral ZEN-012, a Small Molecule Anti-Cancer Agent, in Patients With Advanced Cancer and Lymphoma